• Mashup Score: 0

    Dr. S. Jay Mathews discusses “Patency Restored to an Occluded Femoralfemoral Venous Bypass Graft With the ClotTriever Thrombectomy System” by Mohannad Bisharat, MD.

    Tweet Tweets with this article
    • Leveraging Thrombectomy Tools to Achieve Flow Restoration In this video, Dr. S. Jay Mathews discusses creative applications to leverage #thrombectomy tools to achieve flow restoration, even outside of traditional venous #thromboembolic disease: https://t.co/coYbiuornV https://t.co/13mqS0PU6f

  • Mashup Score: 0

    RFA effectively prevented TEs in patients with giant left atria, despite significant atrial tachyarrhythmia recurrence. Atrial tachyarrhythmia recurrence did not increase the risk of TEs. A lower success rate should be considered when deciding whether to perform surgical ablation in patients with gi …

    Tweet Tweets with this article
    • Advance Online Publication Radiofrequency Ablation in Patients Undergoing Mitral Valve Surgery with or without Giant Left Atria https://t.co/nxOXIZSKEA #giant left atrium, #radiofrequency ablation, #outcome, #competing risk, #thromboembolic events https://t.co/VkAaKdcyHX

  • Mashup Score: 2

    Purpose of Review Venous thromboembolic disease causes significant mortality and morbidity in the oncologic patient population. Recently, minimally invasive endovascular technologies have been developed as an adjunct to antithrombotic therapy for the management of DVT and PE. The current and potential roles for endovascular treatment of cancer-associated venous thromboembolism (VTE) will be…

    Tweet Tweets with this article
    • Hot off the press in Current Oncology Reports! Excellent article by @sirish_kishore et al on the endovascular management of #venous #thromboembolic disease in the #oncologic patient population. A much underutilized treatment option! #irad @SIRspecialists https://t.co/tDDkH4iRZ5 https://t.co/RHCiBBfCe2

  • Mashup Score: 3

    Background Despite vitamin K antagonists (VKA) being the gold standard in the prevention of thromboembolic events in antiphospholipid syndrome (APS), non-vitamin K antagonists oral anticoagulants/direct oral anticoagulants (DOACs) have been used off-label. Objective We aimed to perform a systematic review comparing DOACs to VKA regarding prevention of thromboembolic events, occurrence of…

    Tweet Tweets with this article
    • Do not use direct oral anticoagulants to prevent #thromboembolic events in #antiphospholipid syndrome!⛔ It is associated with 69% increased risk of thromboembolic events compared with vitamin K antagonists according to this meta-analysis https://t.co/j14waELKXf

  • Mashup Score: 0

    A higher proportion of patients with immune-mediated diseases experienced ≥1 thromboembolic events at baseline compared to those without an IMD.

    Tweet Tweets with this article
    • "The elevated risks of #thromboembolic events and the associated risk factors among patients with IMDs should be carefully considered when optimizing treatment to appropriately balance risks and benefits of the chosen therapy in this patient population." https://t.co/gsqvSngYjy